The American Society of Gene & Cell Therapy’s 2026 Annual Meeting opens in Boston on 11 May, bringing together thousands of researchers, clinicians and industry leaders for five days of scientific sessions and discussion.
The global cell and gene therapy sector will gather in Boston this week for the American Society of Gene & Cell Therapy’s 2026 Annual Meeting.
Running from 11 to 15 May at the Thomas M Menino Convention & Exhibition Center in Boston, Massachusetts, the conference is expected to attract thousands of researchers, clinicians, biotech executives, patient advocates and investors from around the world to discuss the latest breakthroughs in genetic medicine and strengthen collaboration across the sector.
Major scientific programme planned
This year’s meeting will build on the momentum of previous conferences, which featured more than 170 sessions, over 750 speakers and upwards of 1,500 scientific posters. ASGCT 2026 will feature expanded coverage of gene editing, RNA technologies, manufacturing innovation and clinical translation.
This year’s event will feature 172 sessions spanning the full breadth of cell and gene therapy alongside more than 250 hours of in-person and on-demand content.
The programme will also feature keynote presentations from internationally recognised scientists and industry leaders, as well as specialist workshops covering the biggest challenges facing the sector, including viral and non-viral delivery systems, manufacturing scale-up, AI applications and next-generation therapeutic platforms.
As the cell and gene therapy sector gathers in Boston for ASGCT 2026, attention is also focusing on the challenge of scaling personalised genomic medicine. Our upcoming webinar: “Manufacturing the Future: From N=1 Personalized CRISPR Therapy to Scalable Precision Genomic Medicine”, will explore how single-patient breakthroughs could be translated into reproducible and commercially viable treatment platforms. Featuring experts from Aldevron, Cytiva, Harvard Medical School and the University of Pennsylvania, the session will examine manufacturing bottlenecks, regulatory pathways and technologies guiding the next generation of precision medicine.
Register for the webinar HERE
Industry leaders and innovators gather
The conference will also serve as a networking hub for biotechnology companies and suppliers looking to showcase new technologies and service offerings, as the organisers put it, “unparalleled access to the global leaders shaping the future of CGT.”
Companies from across the life sciences industry will attend and exhibit at the event. Thermo Fisher Scientific said the event provides “unique opportunities to explore cutting-edge research, stay current on emerging technologies and build career-advancing connections.”
Spotlight on the future of medicine
ASGCT 2026 comes at a time of continued investment and clinical development across the global cell and gene therapy sector.
With a focus on advancing research, education and collaboration in cell and gene therapy, the meeting will bring together researchers, clinicians, industry representatives and patients from across the field. ASGCT continues to serve as a key meeting point for the global cell and gene therapy community.
No comments yet